Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Bimatoprost 0.03% Formulation B Ophthalmic Solution
Bimatoprost 0.03% Formulation B · 1 trial · 2 indications
Change from baseline in worse eye IOP at Week 12 . IOP is a measurement of fluid pressure inside the eye. IOP measurements in the worse eye were evaluated at hours 0, 2, and 8. A negative number change from baseline indicated a reduction in IOP, and a positive number change from baseline indicated an increase in IOP.
Average Eye IOP at Week 12 . IOP is a measurement of fluid pressure inside the eye. IOP measurements were evaluated at hours 0, 2, and 8 in both eyes and the average IOP of both eyes at each time point were reported. Baseline data are included for reference only.
Average Eye IOP at Week 6 . IOP is a measurement of fluid pressure inside the eye. IOP measurements were evaluated at hours 0, 2, and 8 in both eyes and the average IOP of both eyes at each time point were reported.
Average Eye IOP at Week 2 . IOP is a measurement of fluid pressure inside the eye. IOP measurements were evaluated at hours 0, 2, and 8 in both eyes and the average IOP of both eyes at each time point were reported.
| Arm | Type | Description |
|---|---|---|
| Bimatoprost 0.03% Formulation B Ophthalmic Solution | EXPERIMENTAL | Bimatoprost 0.03% Formulation B Ophthalmic Solution |
| Bimatoprost 0.03% Ophthalmic Solution | ACTIVE_COMPARATOR | Bimatoprost 0.03% Ophthalmic Solution |
| Name | Type | Description |
|---|---|---|
| Bimatoprost 0.03% Formulation B Ophthalmic Solution | DRUG | One drop administered in each eye, every evening, for 12 weeks |
| Bimatoprost 0.03% Ophthalmic Solution | DRUG | One drop administered in each eye, every evening, for 12 weeks |
Inclusion Criteria: * Patient has ocular hypertension or glaucoma in both eyes * Requires IOP-lowering therapy in each eye Exclusion Criteria: * Active or recurrent eye disease that would interfere with interpretation of study data in either eye * History of any eye surgery or laser in either eye...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 5 | PHASE3 | Gen 2 Travoprost Intracameral, Timolol eye 0.5% |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Undisclosed |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| Alcon AG | ALC | 5 | N/A | Undisclosed |
| Sight Sciences, Inc. | SGHT | 3 | N/A | Undisclosed |